Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008–2016
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Cardiovascular adverse events (AEs) after use of dipeptidyl peptidase-4 (DPP4) inhibitors have been reported and suspectedsince the launch of DPP-4 inhibitors in 2006. However, few studies have investigated the association between cardiovascularAEs and DPP-4 inhibitors. The objective of this study is to detect the signals of cardiovascular AEs after use of DPP-4 inhibitorsby analyzing the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD). Materials and Methods: Data on the use of oral antidiabetic drugs from 2008 to 2016 were extracted from KIDS-KD, and analyzeddescriptively. Data mining was conducted by calculating three indices, which were proportional reporting ratios, reporting oddsratios, and information components, to detect signals from use of all oral antidiabetic drugs including DPP-4 inhibitors. Then, thesuspected adverse drug reactions (ADRs) were confirmed by signal detection, and drug label information between the KoreaMinistry of Food and Drug Safety and the U.S. Food and Drug Administration were compared. Results: Cardiovascular AEs after taking DPP-4 inhibitors were detected in only three (1.0%) out of a total of 307 AE reports. Twoof the three cardiovascular AEs were reported after using sitagliptin and one using gemiglipitin, but these were not statisticallysignificant. Conclusion: Analysis of spontaneous ADR reports data on the use of DPP-4 inhibitors could not showed the association betweenDPP-4 inhibitors and cardiovascular AEs, due to a small number of cardiovascular AEs reports.
Abstract
Purpose: Cardiovascular adverse events (AEs) after use of dipeptidyl peptidase-4 (DPP4) inhibitors have been reported and suspectedsince the launch of DPP-4 inhibitors in 2006. However, few studies have investigated the association between cardiovascularAEs and DPP-4 inhibitors. The objective of this study is to detect the signals of cardiovascular AEs after use of DPP-4 inhibitorsby analyzing the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System Database (KIDS-KD). Materials and Methods: Data on the use of oral antidiabetic drugs from 2008 to 2016 were extracted from KIDS-KD, and analyzeddescriptively. Data mining was conducted by calculating three indices, which were proportional reporting ratios, reporting oddsratios, and information components, to detect signals from use of all oral antidiabetic drugs including DPP-4 inhibitors. Then, thesuspected adverse drug reactions (ADRs) were confirmed by signal detection, and drug label information between the KoreaMinistry of Food and Drug Safety and the U.S. Food and Drug Administration were compared. Results: Cardiovascular AEs after taking DPP-4 inhibitors were detected in only three (1.0%) out of a total of 307 AE reports. Twoof the three cardiovascular AEs were reported after using sitagliptin and one using gemiglipitin, but these were not statisticallysignificant. Conclusion: Analysis of spontaneous ADR reports data on the use of DPP-4 inhibitors could not showed the association betweenDPP-4 inhibitors and cardiovascular AEs, due to a small number of cardiovascular AEs reports.
참고문헌 (27)
- Lundkvist J, "Pharmacoeconomics of adverse drug reactions", Fundam Clin Pharmacol, 18, pp.275~280 (2004)
- 김민강, "단일기관에서 전산을 통해 수집된 자발적 약물유해반응 보고사례들의 분석", 대한내과학회지, 77(5), pp.601~609 (2009), 대한내과학회
- 최남경, "우리나라 약물유해반응 감시체계", 예방의학회지, 40(4), pp.278~284 (2007), 대한예방의학회
- Edwards IR, "Adverse drug reactions : definitions, diagnosis, and management", Lancet, 356, pp.1255~1259 (2000)
- Hauben M, "The role of data mining in pharmacovigilance", Expert Opin Drug Saf, 4, pp.929~948 (2005)
- "What is a signal?"[URL]
- Health behavior and chronic disease statistics: national health nutrition survey and youth health behavior online survey in 2015, "Korea Centers for Disease Control & Prevention Call Center", Korea Centers for Disease Control, ~ (2016)
- Statistics Korea, "Cause of death of Koreans in 2016", Statistics Korea, ~ (2017)
- Korean Diabetes Association, "Treatment guideline for diabetes", Korean Diabetes Association, ~ (2015)
- Udell JA, "Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes : a metaanalysis of randomised controlled trials", Lancet Diabetes Endocrinol, 3, pp.356~366 (2015)
- Wu S, "Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes : meta-analysis of randomized clinical trials with 55, 141 participants", Cardiovasc Ther, 32, pp.147~158 (2014)
- Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus", N Engl J Med, 369, pp.1317~1326 (2013)
- Green JB, "Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes", N Engl J Med, 373, pp.232~242 (2015)
- Weir DL, "Sitagliptin use in patients with diabetes and heart failure : a population-based retrospective cohort study", JACC Heart Fail, 2, pp.573~582 (2014)
- Wang KL, "Sitagliptin and the risk of hospitalization for heart failure : a population-based study", Int J Cardiol, 177, pp.86~90 (2014)
- Savarese G, "Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients : a meta-analysis", Int J Cardiol, 181, pp.239~244 (2015)
- White WB, "Alogliptin after acute coronary syndrome in patients with type 2 diabetes", N Engl J Med, 369, pp.1327~1335 (2013)
- "Manual for Korea Institute of Drug Safety & Risk Management Korea Adverse Event Reporting System Database"[URL]
- "Reporting adverse drug reactions; definitions of terms and criteria for their use"[URL]
- Poluzzi E, "Data mining applications in engineering and medicine", pp.265~302 (2012), IntechOpen
- Bate A, "Mann’s pharmacovigilance", pp.331~354 (2014), Wiley Blackwell
- Miller RR, "Hospital admissions due to adverse drug reactions. A report from the Boston Collaborative Drug Surveillance Program", Arch Intern Med, 134, pp.219~223 (1974)
- Lazarou J, "Incidence of adverse drug reactions in hospitalized patients : a meta-analysis of prospective studies", JAMA, 279, pp.1200~1205 (1998)
- Raschi E, "Dipeptidyl peptidase-4 inhibitors and heart failure : analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System", Nutr Metab Cardiovasc Dis, 26, pp.380~386 (2016)
- 김민선, "의약품유해사례보고를 통한 아리피프라졸의 실마리정보 검색 및 안전성정보 개발", 대한정신약물학회지, 26(1), pp.10~16 (2015), 대한정신약물학회
- Ministry of Food and Drug Safety White Paper, , Ministry of Food and Drug Safety, ~ (2016)
- 안소현, "일반인에서의 의약품 부작용보고제도 인식도", 보건행정학회지, 24(2), pp.164~171 (2014), 한국보건행정학회[DOI]